Search company, investor...

Alligator Bioscience

Founded Year



Unattributed VC - II | Alive

Total Raised


Last Raised

$10M | 7 yrs ago

About Alligator Bioscience

Alligator Bioscience discovers and develops antibody-based immunotherapies for the treatment of cancer. Alligator Drug Discovery and Development span early research phases with lead identification up to proof of concept phase I/II clinical studies in cancer patients.

Headquarters Location

Medicon Village

Lund, 223 81,


+ 46 (0)46 286 4280

Missing: Alligator Bioscience's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Alligator Bioscience's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Alligator Bioscience

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Alligator Bioscience is included in 3 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

838 items

Alligator Bioscience Patents

Alligator Bioscience has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Transcription factors
  • Immune system
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Immunology, Immune system, Transcription factors, Monoclonal antibodies


Application Date


Grant Date



Related Topics

Clusters of differentiation, Immunology, Immune system, Transcription factors, Monoclonal antibodies



Latest Alligator Bioscience News

Alligator Bioscience announces positive safety data from ATOR-1017 study

Sep 30, 2022

Alligator Bioscience announces positive safety data from ATOR-1017 study 30th September 2022 The research involves patients with advanced solid malignancies on tumour-directed therapy Alligator Bioscience has announced positive safety data from the 900mg dose cohort in its phase 1, first-in-human clinical trial with its drug candidate, ATOR-1017. The treatment is being developed as a tumour-directed therapy for advanced and metastatic cancer. The data also demonstrates that, for doses up to 900mg, there were no significant safety concerns with the therapy, confirming previously announced signs of clinical benefit. Furthermore, no dose-limiting toxicity was observed and the maximum tolerated dose of ATOR-1017 has not been reached. This phase 1 open-label dose-escalation study of ATOR-1017 in patients with histologically confirmed, advanced and/or refractory solid cancer has now completed enrolment while the primary objective of the study – to investigate the safety and tolerability of ATOR-1017 at therapeutic doses – has been successfully met. Two patients are still taking part in the study and are benefitting from ATOR-1017 treatment. "We welcome the latest data from the 900mg dose cohort, the highest dose tested in this trial, which confirms the good safety profile of ATOR-1017," explained Søren Bregenholt, chief executive officer of Alligator Bioscience. “We have observed activation of peripheral T-cells and increased levels of soluble 4-1BB across all active dose levels of ATOR-1017, demonstrating biological activity and proof of mechanism, further validating the therapeutic potential of this drug candidate in solid tumours. This phase 1 study has now successfully fulfilled its purpose and provides a strong foundation for further clinical development," he added. Share

Alligator Bioscience Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Alligator Bioscience Rank

Alligator Bioscience Frequently Asked Questions (FAQ)

  • When was Alligator Bioscience founded?

    Alligator Bioscience was founded in 2000.

  • Where is Alligator Bioscience's headquarters?

    Alligator Bioscience's headquarters is located at Medicon Village, Lund.

  • What is Alligator Bioscience's latest funding round?

    Alligator Bioscience's latest funding round is Unattributed VC - II.

  • How much did Alligator Bioscience raise?

    Alligator Bioscience raised a total of $10M.

  • Who are the investors of Alligator Bioscience?

    Investors of Alligator Bioscience include Johnson & Johnson Innovation, Sunstone Capital, Malmsten Invest, Home Capital, Stena Adactum and 3 more.

  • Who are Alligator Bioscience's competitors?

    Competitors of Alligator Bioscience include Xencor, Aquinox Pharmaceuticals, Reata Pharmaceuticals, Adastra Pharmaceuticals, Actinobac Biomed and 11 more.

Compare Alligator Bioscience to Competitors


NanoMedica aims to become engaged in design,development and manufacture of dual-action therapeutics for the treatment of human cancer.

Y's Therapeutics

Y's Therapeutics focuses on developing monoclonal antibody therapies and other molecular-targeted biological drugs for the treatment of inflammation-mediated diseases, cancer, and other unmet medical needs. The company also have small molecule compounds in the company's R&D pipeline to diversify the company's portfolio.

PNP Therapeutics

PNP Therapeutics is dedicated to the development and commercialization of a cancer treatment approach that is predicated on well-documented evidence that solid tumors can be compelled to develop their own chemotherapy and thus elicit their own self-destruction.

Marillion Pharmaceuticals

Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..

Oxford Genome Sciences (UK)

Oxford BioTherapeuticsis focused on the targeted treatment of cancer.

Bexion Pharmaceuticals

Bexion Pharmaceuticals is a company focused on the development of cures for cancer. Specifically, the company is interested in first entering the clinic with a glioma cancer indication, possibly simultaneously with a leukemia or pancreatic cancer indication.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.